20 June 2019 - People with recurrent non-infectious uveitis affecting the back of the eye could benefit from a new treatment option, the fluocinolone acetonide implant, as a result of new NICE guidance published today.

The treatment, which is injected into the eye, lasts 3 years. This could mean fewer hospital visits for patients who receive current treatments: including corticosteroid injections, immunosuppressants, and dexamethasone and adalimumab implants.

Clinical trial results suggest the fluocinolone acetonide implant may improve clearness of vision for people with uveitis and help prevent the disease returning.

Read NICE press release